Microemulsion as a carrier has been proved to be useful, specifically for agents having poor water solubility, as O/W microemulsion.\[[@ref1]\] Antihypertensive agent Felodipine (FLD) (Dihydro-pyridine class calcium channel blocker) is absorbed throughout the gastro-intestinal tract. FLD is having very poor water solubility (0.8 *μ*g/ml). So, solubility is the major barrier for the formulation development. Microemulsion can be used as drug carrier in which drug is incorporated into droplet structure (size 10 nm to 200 nm), leading to dissolution rate enhancement.\[[@ref2]\]

Materials and Methods {#sec1-1}
=====================

All the ingredients of the formulation were chosen on the safety and solubility basis. The FLD was obtained as gift sample from Cipla Ltd (Mumbai). Isopropyl myristate, cremophor el, PEG 400, castor oil, tween 80, tween 20 were purchased from the Himedia Ltd. (Mumbai), and propylene glycol was purchased from Merck Inc. (Mumbai). All other ingredients were purchased of AR grade.

Ingredients were subjected to the solubility study. For this study excess of FLD was added into various components and then was subjected to the vortexing for 15 minutes and mixing for the 48 hours, after that the spectrophotometric determination was carried out. After quantification, the major components chosen were isopropyl myristate (IPM) (as Oil), cremophor-el (CEL) (as Surfactant) and propylene glycol (PG) (as Cosurfactant).

The phase study was carried out using IPM: CEL: PG: WATER with different ratios of the CEL: PG. From the phase diagram the microemulsion region was selected which had the greatest area covering the phase diagram. The 2^2^ factorial design was applied for the screening of the microemulsion using the independent factors as amount of oil and surfactant and the dependent factors as particle size (PSA) and viscosity. The selected microemulsion was subjected to the various characterizations like DLS, pH, conductivity, transparency, viscosity etc. The stability of the microemulsion at room temperature, at 2°C and against centrifugal force was checked for the 1 month period.

Results and Discussion {#sec1-2}
======================

Solubility study was carried out and IPM was selected as oil (25 mg/ml). The other components chosen were CEL, PG as surfactant and cosurfactant. Phase study shows the CEL: PG (3:1) ratio as a widest microemulsion region containing composition. From the 2^2^ factorial design (Design Expert 8.0.7.1, Stat-Ease Inc., Minnesota, USA) the analysis of the PSA \[[Figure 1](#F1){ref-type="fig"}\] and viscosity \[[Figure 2](#F2){ref-type="fig"}\] as the factorial model could be plotted as below.

![Contour and 3D surface plot for PSA as dependent factor](JPBS-4-69-g001){#F1}

![Contour and 3D surface plot for viscosity as dependent factor](JPBS-4-69-g002){#F2}

Selected formulation was having 97.3nm z-average size(Malvern Zetasizer ns 90), p. 5.6 (Elico pH meter), conductivity 65 *μ*S/ cm(EC-TDS Analyzer), transparency as % transmittance measurement which was 99.1% at 620 nm (UV 1800 Shimadzu) and viscosity was 70 cPs (Brookfield Viscometer-LVT). Microemulsion formulation showed *in-vitro* release up to 98% in 1 hour. Microemulsion formulation showed 5000-10000 times enhancement of solubility in comparison to the absolute solubility.

Conclusion {#sec1-3}
==========

The formulated microemulsion succeeded in achieving the dissolution barrier of the FLD. Thus it aid in the formulation and administration of the FLD leading to improved compliance and dosage delivery.

The Authors are thankful to the Cipla Ltd. (Mumbai) for the gift sample of FLD. The authors are thankful to the RPCP (CHARUSAT) for providing necessary facility for the research work.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
